Navigation Links
Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2013
Date:7/25/2013

>

National Center for Complementary and Alternative Medicine 69

Clinical Trial Overview of National Center for Complementary and Alternative Medicine 69

Oregon Health and Science University 70

Clinical Trial Overview of Oregon Health and Science University 70

Columbia University 71

Clinical Trial Overview of Columbia University 71

Virginia Commonwealth University 72

Clinical Trial Overview of Virginia Commonwealth University 72

Skane University Hospital 73

Clinical Trial Overview of Skane University Hospital 73

National Institute of Neurological Disorders and Stroke 74

Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 74

H. Lee Moffitt Cancer Center & Research Institute 75

Clinical Trial Overview of H. Lee Moffitt Cancer Center & Research Institute 75

Five Key Clinical Profiles 76

Appendix 200

Abbreviations 200

Definitions 200

Research Methodology 201

Secondary Research 201

About GlobalData 202

Contact Us 202

Disclaimer 202

Source 203

 

List of Tables

 

Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Market, Global, Clinical Trials by Zone, 2013* 9

Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 10

Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 11

Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2013* 12

Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Clinical Trials, Europe, Top Five Countries, 2013* 13

Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Clinical Trials, North America, Top Countries,
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovios Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
2. Peripheral Vascular Devices Market (Peripheral Vascular Stents, PTA Balloon Catheters, Guidewires, IVC Filters, Atherectomy, Chronic Total Occlusion, Embolic Protection Devices, Synthetic Surgical Grafts, Aortic Stents) - Global Industry Analysis, S
3. QualiMed Innovative Medizinprodukte GmbH, Based in Winsen Germany has Received Notice of CE Approval for its Line of Peripheral Balloons for the Treatment of Peripheral Vascular Obstructions
4. US Peripheral Vascular Device Market to Grow Strongly to $3.3 Billion by 2017
5. Peripheral Vascular Devices Market to 2018 - Increasing Demand for Minimally Invasive Endovascular Procedures Presents Growth Opportunities for Manufacturers
6. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
7. Anesthesia Equipment and Associated Peripherals: Advanced, Patient-Friendly Devices Will Sustain Market Growth in Europe, States Frost & Sullivan
8. Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
9. Global Peripheral Vascular Devices Market 2011-2015
10. Brazil Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others
11. North America Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology Prosthetic Heart Valves and Others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 /PRNewswire-iReach/ -- The global microbial ... products, methods, applications, end users, and geographies. Genotypic ... the microbial identification market. This favorable growth is ... test) and the time required for microbial identification ... advancements. Furthermore, genotypic methods have high applications in ...
(Date:7/29/2014)... Calif., July 29, 2014 Amgen (NASDAQ: ... second quarter of 2014. Key results include: , ... 8 percent product sales growth driven by strong performance ... ® (carfilzomib), Prolia ® (denosumab) and XGEVA ... percent to $2.37, driven by higher revenues and a ...
(Date:7/29/2014)...  Express Scripts Holding Company (Nasdaq: ESRX ... Express Scripts stockholders of $515.2 million, or $0.67 per ... in Table 4, was $1.23 for the second quarter. ... serve our clients with scale, alignment and innovative solutions to ... outcomes of our members," stated George Paz, chairman and chief ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7
... GARDEN CITY, New York, Oct. 7 ... Merkin recognize and congratulate seniors enrolled with HCP, IPA ... concern, health care reform, directly to members of Congress, ... http://www.newscom.com/cgi-bin/prnh/20091007/LA89266 ) , Dr. John Gastright, Senior ...
... , WALTHAM, Mass., Oct. 7 Nova Biomedical Corporation, ... that the company,s independent, wholly owned subsidiary, Sanvita CBGM, ... Sanvita, Inc., a subsidiary of CCS Medical, Inc. ... through this transaction, Nova,s Consumer Blood Glucose Monitoring (CBGM) ...
Cached Medicine Technology:HealthCare Partners, IPA, Dr. Richard Merkin, CEO, Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington, DC 2HealthCare Partners, IPA, Dr. Richard Merkin, CEO, Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington, DC 3Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medical's Subsidiary, Sanvita, Inc. 2
(Date:7/29/2014)... 29, 2014 Daily Gossip reveals in its ... a holistic nutritional and functional medicine practitioner, who spent years ... problem. , Karen suffered from leaky gut, too, so this ... develop this unique treatment. , Karen Brimeyer decided to ... from all around the world. The author of the Leaky ...
(Date:7/29/2014)... July 29, 2014 DailyGossip.org reveals in ... actually is a new method of naturally overcoming sciatica, ... of the new method ensure sufferers that the cure ... recommendations. , The new method is described as ... overcome sciatica with an 8 minutes per day treatment ...
(Date:7/29/2014)... For numerous women from all over the world, finding love, ... quite hard. Well, the author of the Make Him Desire ... help all these women. This is the formula that will ... attention every day. , Daily Gossip reveals in its ... Carter who published a unique eBook to detail it. ...
(Date:7/29/2014)... 29, 2014 Winter is here down ... afternoon in Sydney’s central business district. That is, until ... costume transformed the otherwise ordinary day into a celebration—a ... are ardent advocates of The Truth About Drugs, a ... Scientology . They woke up the city with a ...
(Date:7/29/2014)... July 29, 2014 Parker Waichman LLP, ... of victims injured by defective drugs and medical devices, ... by plaintiffs in Canada who allege that they were ... with the low testosterone injection Delatestryl (Court File ... 2014 in the Ontario Superior Court of Justice. , ...
Breaking Medicine News(10 mins):Health News:Leaky Gut Cure Review Reveals Karen Brimeyer’s Natural Way to Heal Leaky Gut 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2Health News:"Make Him Desire You" Review Reveals Unique Formula to Make Men Feel a Special Kind of Love 2Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3
... reducing weight and increasing exercise cut the risk of ... sugar are known to be at increased risk of ... complications, it would be very useful if there was ... disease. ,Researchers for the Diabetes Prevention Programme ...
... food meals may be quick and easy, but no matter ... fat. Now there is new reason to restrict the junk ... Nestel, of melbourne's Baker Medical Research Institute, fed 10 volunteers ... butter, whole milk and ice cream (the meal delivered 50 ...
... that Women who smoke while pregnant are 60 percent to ... a baby with a cleft lip or palate. The risk ... that a mother-to-be smokes each day, even after factors like ... finding, based on the largest-ever examination of cleft lip and ...
... was initially lauded as a major breakthrough for women ... their// prescription because of the drug's rigid dosing instructions: ... minutes before eating, and downed with plenty of water. ... indigestion. ,So scientists tried giving women a week's ...
... composition and anti-oxidant content are associated with ... derived from diabetic patients.//Researchers designed a study ... from patients with diabetes mellitus to normoglycemic ... effects of dietary beta-carotene supplementation on LDL ...
... yet another good reason to exercise regularly. We know that ... our risk of heart disease and stroke,// and it even ... also good for reducing our risk of ovarian cancer. ... very appropriate. That makes it all the more important to ...
Cached Medicine News:
... PM Ophthalmology, VitalWorks OptiShop simpli?es ... shop. From ordering to inventory ... OptiShop is designed to address ... todays optical shops, and to ...
... Materials Management / Purchasing ... Procedure Room, Technicians and Physician ... scheduling for each Doctor and ... Patient Facility Billing, Automated Patient ...
Compulink is among today's leaders in the ophthalmic practice management market. Compulink's Ophthalmology Advantage integrates all the functionality of a busy Ophthalmic practice needs, while keepin...
... Optimeyes™ MBA is a complete ... written specifically for optometrists, opticians and ... and Macintosh users seeking a graphically ... a full complement of solid features ...
Medicine Products: